• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多替拉韦在离体人胎盘绒毛叶灌流模型中的胎盘转运和组织蓄积。

Placental transfer and tissue accumulation of dolutegravir in the ex vivo human cotyledon perfusion model.

机构信息

Assistance Publique-Hôpitaux de Paris, Hôpital Louis Mourier, Service de Gynécologie-Obstétrique, Hôpitaux Universitaires Paris-Nord Val de Seine, Colombes, France.

Université Paris-Diderot, Université Sorbonne Paris-Cité, Paris, France.

出版信息

PLoS One. 2019 Aug 13;14(8):e0220323. doi: 10.1371/journal.pone.0220323. eCollection 2019.

DOI:10.1371/journal.pone.0220323
PMID:31408460
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6692001/
Abstract

OBJECTIVE

To determine the transplacental pharmacokinetics of the HIV integrase inhibitor dolutegravir.

STUDY DESIGN

Maternal-to-fetal transfer across the term human placenta was investigated with the ex-vivo dually perfused cotyledon model, in 5 closed-circuit, recirculating experiments. Dolutegravir was added to a maternal perfusate containing antipyrine, a marker to validate the cotyledon's viability, and 2 g/liter of human albumin.

RESULTS

After 3h of recirculating perfusion, the mean (± SD) DTG concentrations in the maternal and in the fetal compartments were respectively 2450 ± 286 ng/mL and 715 ± 369 ng/mL, with a fetal-to-maternal ratio of 34% ± 18% and a clearance index (in comparison with antipyrine transfer) of 79% ± 23%. The mean cotyledon accumulation index was 153% ± 25%.

CONCLUSION

Fetal transplacental exposure to dolutegravir was considerable as well as accumulation in placental tissue. Whether this may lead to risks for the exposed fetus requires more investigation.

摘要

目的

研究人类胎盘中 HIV 整合酶抑制剂多替拉韦的跨胎盘药代动力学。

研究设计

采用离体双灌流绒毛模型,在 5 个闭路、再循环实验中研究了足月时母体到胎儿的转移。多替拉韦被添加到含有安替比林(一种验证绒毛膜活力的标志物)和 2 g/L 人白蛋白的母体灌流液中。

结果

再循环灌注 3 小时后,母、胎儿腔室中多替拉韦的平均(±SD)浓度分别为 2450 ± 286ng/ml 和 715 ± 369ng/ml,胎儿与母体的比值为 34% ± 18%,清除指数(与安替比林转移相比)为 79% ± 23%。平均胎盘组织蓄积指数为 153% ± 25%。

结论

胎儿通过胎盘暴露于多替拉韦的程度以及在胎盘组织中的蓄积量都相当可观。这是否会给暴露的胎儿带来风险,还需要进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ee0/6692001/f51eb2d2b978/pone.0220323.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ee0/6692001/f51eb2d2b978/pone.0220323.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ee0/6692001/f51eb2d2b978/pone.0220323.g001.jpg

相似文献

1
Placental transfer and tissue accumulation of dolutegravir in the ex vivo human cotyledon perfusion model.多替拉韦在离体人胎盘绒毛叶灌流模型中的胎盘转运和组织蓄积。
PLoS One. 2019 Aug 13;14(8):e0220323. doi: 10.1371/journal.pone.0220323. eCollection 2019.
2
Placental transfer of the integrase strand inhibitors cabotegravir and bictegravir in the ex-vivo human cotyledon perfusion model.整合酶抑制剂卡替拉韦和比克替拉韦在离体人胎盘绒毛叶灌流模型中的胎盘转运。
AIDS. 2020 Nov 15;34(14):2145-2149. doi: 10.1097/QAD.0000000000002637.
3
Placental transfer of the HIV integrase inhibitor dolutegravir in an ex vivo human cotyledon perfusion model.在体外人胎盘小叶灌注模型中HIV整合酶抑制剂多替拉韦的胎盘转运
J Antimicrob Chemother. 2016 Feb;71(2):480-3. doi: 10.1093/jac/dkv358. Epub 2015 Nov 3.
4
Placental transfer of elvitegravir and cobicistat in an ex-vivo human cotyledon double perfusion model.elvitegravir 和考比司他在体外人胎盘中的转移:双灌流模型研究。
AIDS. 2018 Jan 28;32(3):321-325. doi: 10.1097/QAD.0000000000001681.
5
Placental transfer of doravirine, a recent HIV-1 NNRTI in the ex vivo human cotyledon perfusion model.在体外人胎盘绒毛叶灌注模型中研究新型 HIV-1 NNRTI 地拉韦啶的胎盘转运。
J Antimicrob Chemother. 2021 Aug 12;76(9):2364-2367. doi: 10.1093/jac/dkab202.
6
Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling.整合胎盘体外灌流数据和基于生理的药代动力学模型评估母体和胎儿多替拉韦暴露情况。
Clin Pharmacol Ther. 2020 Jun;107(6):1352-1361. doi: 10.1002/cpt.1748. Epub 2020 Jan 24.
7
Determination of metformin transfer across the human placenta using a dually perfused ex vivo placental cotyledon model.使用双灌注离体胎盘小叶模型测定二甲双胍在人胎盘的转运情况。
Eur J Obstet Gynecol Reprod Biol. 2008 Jan;136(1):29-33. doi: 10.1016/j.ejogrb.2007.01.013. Epub 2007 Mar 12.
8
Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model.雷特格韦在体外人胎盘小叶灌注模型中的双向转运
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3112-4. doi: 10.1128/AAC.00007-16. Print 2016 May.
9
Transplacental passage of vancomycin in the ex vivo human perfusion model.万古霉素在体外人灌注模型中的胎盘转运。
Infect Dis Obstet Gynecol. 2004 Jun;12(2):57-61. doi: 10.1080/10647440400009821.
10
Transplacental pharmacokinetics of diclofenac in perfused human placenta.双氯芬酸在灌注人胎盘中的经胎盘药代动力学
Drug Metab Dispos. 2009 May;37(5):962-8. doi: 10.1124/dmd.108.024349. Epub 2009 Feb 9.

引用本文的文献

1
Risk of Congenital Anomalies with Dolutegravir-Based Anti-retroviral Regimens: A Systematic Review and Meta-analysis.多替拉韦为基础的抗逆转录病毒方案致先天畸形的风险:系统评价和荟萃分析。
Clin Drug Investig. 2024 Sep;44(9):667-685. doi: 10.1007/s40261-024-01390-y. Epub 2024 Sep 20.
2
Safety and Efficacy of Antiviral Drugs and Vaccines in Pregnant Women: Insights from Physiologically Based Pharmacokinetic Modeling and Integration of Viral Infection Dynamics.抗病毒药物和疫苗在孕妇中的安全性与有效性:基于生理的药代动力学建模及病毒感染动力学整合的见解
Vaccines (Basel). 2024 Jul 16;12(7):782. doi: 10.3390/vaccines12070782.
3

本文引用的文献

1
Assessing the risk of dolutegravir for women of childbearing potential.评估多替拉韦对有生育潜力女性的风险。
Lancet Glob Health. 2018 Sep;6(9):e958-e959. doi: 10.1016/S2214-109X(18)30326-7. Epub 2018 Jul 23.
2
Dolutegravir for HIV: a lesson in pregnancy safety research.多替拉韦用于治疗HIV:妊娠安全性研究的一个教训。
Lancet. 2018 Jun 9;391(10137):2296. doi: 10.1016/S0140-6736(18)31265-0.
3
In-utero ART exposure and the need for pharmacovigilance.子宫内辅助生殖技术暴露与药物警戒的必要性。
Fetus Exposure to Drugs and Chemicals: A Holistic Overview on the Assessment of Their Transport and Metabolism across the Human Placental Barrier.
胎儿对药物和化学物质的暴露:关于评估其在人胎盘屏障中的转运和代谢的全面概述。
Diseases. 2024 Jun 1;12(6):114. doi: 10.3390/diseases12060114.
4
Gene-nutrient interactions that impact magnesium homeostasis increase risk for neural tube defects in mice exposed to dolutegravir.影响镁稳态的基因-营养素相互作用会增加暴露于多替拉韦的小鼠发生神经管缺陷的风险。
Front Cell Dev Biol. 2023 Jun 12;11:1175917. doi: 10.3389/fcell.2023.1175917. eCollection 2023.
5
Inhibition of matrix metalloproteinases by HIV-1 integrase strand transfer inhibitors.HIV-1整合酶链转移抑制剂对基质金属蛋白酶的抑制作用
Front Toxicol. 2023 Feb 21;5:1113032. doi: 10.3389/ftox.2023.1113032. eCollection 2023.
6
HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment.HIV-1整合酶链转移抑制剂与神经发育
Pharmaceuticals (Basel). 2022 Dec 9;15(12):1533. doi: 10.3390/ph15121533.
7
Second-Generation Human Immunodeficiency Virus Integrase Inhibitors Induce Differentiation Dysregulation and Exert Toxic Effects in Human Embryonic Stem Cell and Mouse Models.第二代人类免疫缺陷病毒整合酶抑制剂诱导人类胚胎干细胞和小鼠模型分化失调并产生毒性作用。
J Infect Dis. 2022 Nov 28;226(11):1992-2001. doi: 10.1093/infdis/jiac386.
Lancet Glob Health. 2018 Jul;6(7):e716-e717. doi: 10.1016/S2214-109X(18)30272-9. Epub 2018 Jun 4.
4
Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.博茨瓦纳开展的一项观察性研究:在孕期开始使用多替拉韦或依非韦伦为基础的抗逆转录病毒治疗的安全性比较。
Lancet Glob Health. 2018 Jul;6(7):e804-e810. doi: 10.1016/S2214-109X(18)30218-3. Epub 2018 Jun 4.
5
Placental transfer of elvitegravir and cobicistat in an ex-vivo human cotyledon double perfusion model.elvitegravir 和考比司他在体外人胎盘中的转移:双灌流模型研究。
AIDS. 2018 Jan 28;32(3):321-325. doi: 10.1097/QAD.0000000000001681.
6
Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding.迈向通用抗逆转录病毒疗法:妊娠和母乳喂养的特殊考量
Curr Opin HIV AIDS. 2017 Jul;12(4):359-368. doi: 10.1097/COH.0000000000000386.
7
Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy.孕期埃替格韦、度鲁特韦及其他抗逆转录病毒药物的药代动力学和胎盘转运
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.02213-16. Print 2017 Jun.
8
A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways.一种基于生理学的药代动力学模型,用于预测经多种细胞色素P450途径代谢的药物对人类胎儿的暴露情况。
Clin Pharmacokinet. 2017 May;56(5):537-550. doi: 10.1007/s40262-016-0457-5.
9
Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing.多替拉韦在孕期的药代动力学早期经验:每日两次给药时母体血药浓度高且胎儿药物暴露显著
AIDS. 2016 May 15;30(8):1313-5. doi: 10.1097/QAD.0000000000001055.
10
Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model.雷特格韦在体外人胎盘小叶灌注模型中的双向转运
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3112-4. doi: 10.1128/AAC.00007-16. Print 2016 May.